Recently, Aikang Biotechnology, a firm committed to the research and development of AI-driven iPSC (induced pluripotent stem cell) cell therapy medications, has announced the successful closure of its Series A3 financing round, amassing over RMB 100 million. This financing round was co-led by Zhiyi Investment and Wojie Capital, with further support from Union New Capital. The capital raised will be earmarked for advancing the clinical trials of multiple allogeneic universal iPSC-derived cellular new drugs and for refining the strategic layout of the technology platform.

Established in March 2021, Aikang Biotechnology has forged a path for iPSC cell drug development through an AI-driven predictive modeling system. At present, the global iPSC cell therapy sector is rapidly progressing towards industrialization, with Japan poised to conditionally approve two iPSC-derived regenerative medical products for market release in February 2026.

Leveraging artificial intelligence as its core driving force, Aikang Biotechnology has constructed an AI-driven research and development platform, with a focus on neurological diseases. Its iPSC-derived dopaminergic precursor cell therapy for Parkinson's disease has demonstrated positive results in IIT (Investigator-Initiated Trial) clinical studies, and several products targeting conditions such as epilepsy have entered the IND (Investigational New Drug) application phase. Furthermore, the company has established an AI + iPSC organoid platform and set up research and development, clinical, and production bases across multiple locations. It is actively collaborating with international clinical institutions to pave the way for global expansion and advancement.